Navigation Links
Neurobiological Technologies Sets Date for Third Quarter Financial Results
Date:5/8/2008

EMERYVILLE, Calif., May 8 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its third quarter 2008 financial results, for the quarter ended March 31, 2008, on May 12, 2008 and host a conference call on May 13, 2008.

Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Matthew M. Loar, Vice President and Chief Financial Officer. The details for the call are as follows:

-- Date: Tuesday, May 13, 2008

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 877-591-4953 U.S. / 719-325-4851 International

Web cast of call: A live web cast can be accessed online by going to:

http://investor.shareholder.com/ntii/events.cfm

The call will be archived and accessible at the same website for 90 days

Telephonic Replay: A playback of the conference call will be available

from 1:30 pm (ET) on May 13, 2008 to midnight on May 17, 2008. Reply

number:

888-203-1112 U.S. / 719-457-0820 International Pass code: 3838724

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug with multiple mechanisms of action that is specifically designed to double the time period that patients can be treated after the onset of a stroke. NTI also has the right to receive royalty payments from sales of Namenda(R) (memantine HCL), an approved drug marketed for Alzheimer's disease, and the right to receive payments from the development and marketing of XERECEPT(R) (corticorelin acetate injection), an investigational drug in Phase 3 clinical development for swelling associated with brain tumors. Additionally, NTI has rights to two compounds in early-stage development for Alzheimer's and Huntington's diseases.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
3. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
4. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. Neurobiological Technologies Sets Date for Second Quarter Financial Results
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a ... with a flexure design that ensures high alignment accuracy by preventing unwanted shaft ... ideally suited where extreme precision is required, such as in medical equipment, laboratory ...
(Date:11/30/2016)...  The Allen Institute for Cell Science has ... available collection of gene edited, fluorescently tagged human ... structures with unprecedented clarity. Distributed through the Coriell ... a crucial first step toward visualizing the dynamic ... human cells healthy and what goes wrong in ...
(Date:11/30/2016)... Part of 5m$ Investment in Integrated Drug Discovery ... , ... announced that it had successfully completed the expansion of their ... the Screening Collection to over 400,000. The new compounds were ... company. This expansion, complemented by new robotics and compound management ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... On 28 ... and symbols for four elements: nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson ... of public review, the names earlier proposed by the discoverers have been approved by ...
Breaking Biology Technology:
(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
(Date:11/22/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the company ... Life Sciences Awards as "Most Outstanding in eClinical ... year of recognition and growth for MedNet, which has ... iMedNet ™ , MedNet,s flagship ...
(Date:11/17/2016)... , Nov. 17, 2016  AIC announces that it has just released a new ... that require high-performance scale-out plus high speed data transfer storage solutions. Photo ... ... ... Setting up a high performance computing ...
Breaking Biology News(10 mins):